Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
McKesson
Baxter
Mallinckrodt

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,700,555

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,700,555
Title:Bromocriptine formulations
Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI), Bowe; Craig Michael (Encinitas, CA), Stearns; Paul Clark (San Diego, CA), Weston; Laura Jean (Escondido, CA)
Assignee: VeroScience LLC (Tiverton, RI)
Application Number:15/286,826
Patent Claims: 1. A dosage form comprising: bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of about 10 .mu.m or lower; and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.

2. The dosage form of claim 1, wherein the bromocriptine is in the form of a salt of bromocriptine.

3. The dosage form of claim 1, wherein the bromocriptine is in the form of bromocriptine mesylate.

4. The dosage form of claim 1, wherein the dosage form is in the form of a tablet.

5. The dosage form of claim 1, wherein the bromocriptine is in micronized form.

6. The dosage form of claim 1, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

7. The dosage form of claim 1, wherein the bromocriptine has volume-based particle size distribution with a span of about 2.5 or lower.

8. The dosage form of claim 1, wherein the bromocriptine has volume-based particle size distribution with a span of about 2 or lower.

9. The dosage form of claim 1, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes.

10. The dosage form of claim 1, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

11. The dosage form of claim 1, wherein the wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

12. The dosage form of claim 1, wherein: the bromocriptine is in the form of bromocriptine mesylate; the dosage form is in the form of a tablet; not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m; the bromocriptine has volume-based particle size distribution with a span of about 2 or lower; the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, not more than about 75% of the bromocriptine has been released at about 10 minutes, and at least about 80% of the bromocriptine has been released at about 30 minutes; and the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

13. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 1.

14. The method of claim 13, wherein the dosage form is administered in the morning within about two hours after waking.

15. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.

16. The dosage form of claim 15, wherein the bromocriptine is in the form of a salt of bromocriptine.

17. The dosage form of claim 15, wherein the bromocriptine is in the form of bromocriptine mesylate.

18. The dosage form of claim 15, wherein the dosage form is in the form of a tablet.

19. The dosage form of claim 15, wherein the bromocriptine has a Dv90 of about 20 .mu.m or lower.

20. The dosage form of claim 15, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

21. The dosage form of claim 15, wherein the bromocriptine has volume-based particle size distribution with a span of about 2.5 or lower.

22. The dosage form of claim 15, wherein the bromocriptine has volume-based distribution particle size such that the particle size span is about 2 or lower.

23. The dosage form of claim 15, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes.

24. The dosage form of claim 15, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

25. The dosage form of claim 15, wherein the wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

26. The dosage form of claim 15, wherein: the bromocriptine is in the form of bromocriptine mesylate; the dosage form is in the form of a tablet; not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m; the bromocriptine has volume-based particle size distribution with a span of about 2 or lower; the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, not more than about 75% of the bromocriptine has been released at about 10 minutes, and at least about 80% of the bromocriptine has been released at about 30 minutes; and the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

27. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 15.

28. The method of claim 27, wherein the dosage form is administered in the morning within about two hours after waking.

29. A dosage form comprising: bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of about 15 .mu.m or lower; wherein the bromocriptine has a particle size distribution with a span of about 2 or lower; and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.

30. The dosage form of claim 29, wherein the bromocriptine is in the form of a salt of bromocriptine.

31. The dosage form of claim 29, wherein the bromocriptine is in the form of bromocriptine mesylate.

32. The dosage form of claim 29, wherein the dosage form is in the form of a tablet.

33. The dosage form of claim 29, wherein the bromocriptine is in micronized form.

34. The dosage form of claim 29, wherein the bromocriptine has a Dv90 of about 10 .mu.m or lower.

35. The dosage form of claim 29, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

36. The dosage form of claim 29, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes.

37. The dosage form of claim 29, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

38. The dosage form of claim 29, wherein the wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

39. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 29.

40. The method of claim 39, wherein the dosage form is administered in the morning within about two hours after waking.

41. A dosage form comprising: bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered orally to a subject; wherein the bromocriptine has a Dv99 of less than about 15 .mu.m; and wherein the dosage form has a dissolution profile wherein at least about 80% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

42. The dosage form of claim 41, wherein the bromocriptine is in the form of a salt of bromocriptine.

43. The dosage form of claim 41, wherein the bromocriptine is in the form of bromocriptine mesylate.

44. The dosage form of claim 41, wherein the dosage form is in the form of a tablet.

45. The dosage form of claim 41, wherein the bromocriptine is in micronized form.

46. The dosage form of claim 41, wherein the bromocriptine has a Dv90 of less than about 10 .mu.m.

47. The dosage form of claim 41, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

48. The dosage form of claim 41, wherein the bromocriptine has volume-based particle size distribution with a span of about 2 or lower.

49. The dosage form of claim 41, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes.

50. The dosage form of claim 41, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

51. The dosage form of claim 41, wherein the wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

52. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 41.

53. The method of claim 52, wherein the dosage form is administered in the morning within about two hours after waking.

54. A dosage form comprising: bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine is in a form has a Dv90 of less than about 10 .mu.m; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

55. The dosage form of claim 54, wherein the bromocriptine is in the form of a salt of bromocriptine.

56. The dosage form of claim 54, wherein the bromocriptine is in the form of bromocriptine mesylate.

57. The dosage form of claim 54, wherein the dosage form is in the form of a tablet.

58. The dosage form of claim 54, wherein the bromocriptine is in micronized form.

59. The dosage form of claim 54, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

60. The dosage form of claim 54, wherein the bromocriptine has volume-based particle size distribution with a span of about 2.5 or lower.

61. The dosage form of claim 54, wherein the bromocriptine has volume-based particle size distribution with a span of about 2 or lower.

62. The dosage form of claim 54, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes and at least about 80% of the bromocriptine has been released at about 30 minutes.

63. The dosage form of claim 54, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

64. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 54.

65. The method of claim 64, wherein the dosage form is administered in the morning within about two hours after waking.

66. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of less than about 20 .mu.m; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

67. The dosage form of claim 66, wherein the bromocriptine is in the form of a salt of bromocriptine.

68. The dosage form of claim 66, wherein the bromocriptine is in the form of bromocriptine mesylate.

69. The dosage form of claim 66, wherein the dosage form is in the form of a tablet.

70. The dosage form of claim 66, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

71. The dosage form of claim 66, wherein the bromocriptine has volume-based particle size distribution with a span of about 2.5 or lower.

72. The dosage form of claim 66, wherein the bromocriptine has volume-based particle size distribution with a span of about 2 or lower.

73. The dosage form of claim 66, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes and at least about 80% of the bromocriptine has been released at about 30 minutes.

74. The dosage form of claim 66, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

75. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 66.

76. The method of claim 75, wherein the dosage form is administered in the morning within about two hours after waking.

77. A dosage form comprising: bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of about 15 .mu.m or lower; wherein the bromocriptine has a particle size distribution with a span of about 2 or lower; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

78. The dosage form of claim 77, wherein the bromocriptine is in the form of a salt of bromocriptine.

79. The dosage form of claim 77, wherein the bromocriptine is in the form of bromocriptine mesylate.

80. The dosage form of claim 77, wherein the dosage form is in the form of a tablet.

81. The dosage form of claim 77, wherein the bromocriptine is in micronized form.

82. The dosage form of claim 77, wherein the bromocriptine has a Dv90 of about 10 .mu.m or lower.

83. The dosage form of claim 77, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

84. The dosage form of claim 77, wherein the bromocriptine has volume-based particle size distribution with a span of about 2 or lower.

85. The dosage form of claim 77, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes and at least about 80% of the bromocriptine mesylate has been released at about 30 minutes.

86. The dosage form of claim 77, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

87. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 77.

88. The method of claim 87, wherein the dosage form is administered in the morning within about two hours after waking.

89. A dosage form comprising bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered orally to a subject; wherein the bromocriptine has a Dv99 of less than about 15 .mu.m; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

90. The dosage form of claim 89, wherein the bromocriptine is in the form of a salt of bromocriptine.

91. The dosage form of claim 89, wherein the bromocriptine is in the form of bromocriptine mesylate.

92. The dosage form of claim 89, wherein the dosage form is in the form of a tablet.

93. The dosage form of claim 89, wherein the bromocriptine is in micronized form.

94. The dosage form of claim 89, wherein the bromocriptine has a Dv90 of less than about 10 .mu.m.

95. The dosage form of claim 89, wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

96. The dosage form of claim 89, wherein the bromocriptine has volume-based particle size distribution with a span of about 2 or lower.

97. The dosage form of claim 89, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine has been released at about 7 minutes, and not more than about 75% of the bromocriptine has been released at about 10 minutes and at least about 80% of the bromocriptine has been released at about 30 minutes.

98. The dosage form of claim 89, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine has been released at about 30 minutes.

99. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 89.

100. The method of claim 99, wherein the dosage form is administered in the morning within about two hours after waking.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
Dow
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.